1 |
NCT02896413 |
Recruiting |
The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection |
|
- Drug: Dexmedetomidine group
- Drug: Control group
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
|
- natural killer cell cytotoxicity
- inflammatory response
|
100 |
Female |
20 Years to 70 Years (Adult, Senior) |
NCT02896413 |
4-2015-0453 |
|
May 2016 |
May 2018 |
May 2018 |
September 12, 2016 |
September 12, 2016 |
|
- Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institue, Yonsei Universiy College of Medicine
Seoul, Korea, Republic of
|
2 |
NCT01600040 |
Recruiting |
Proton Beam Teletherapy for Post-Hysterectomy Cancers of the Uterus and Cervix |
- Uterine Cancer
- Cervical Cancer
|
- Radiation: Proton radiation therapy
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Magnitude of radiation dose reductions
- Radiation side effects and delayed complications
- QOL
- Progression-free survival
|
30 |
Female |
18 Years and older (Adult, Senior) |
NCT01600040 |
10-269 |
|
May 2013 |
May 2019 |
May 2021 |
May 16, 2012 |
November 6, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
3 |
NCT02528864 |
Recruiting |
MRI and Metabolomics Biomarkers for Uterine Malignancy |
|
|
Observational |
|
- Chang Gung Memorial Hospital
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
|
150 |
Female |
20 Years to 80 Years (Adult, Senior) |
NCT02528864 |
103-7316A3 |
EMCAMRS |
August 2015 |
July 2018 |
July 2018 |
August 19, 2015 |
August 15, 2016 |
|
- Department of Medical Imaging and Intervention, Chang Gung Memorial Hospital
Guishan, Taoyuan, Taiwan
|
4 |
NCT03192059 |
Recruiting |
Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer |
- Cervical Cancer
- Endometrial Cancer
- Uterine Cancer
|
- Drug: Pembrolizumab
- Radiation: Radiation
- Drug: Vitamin D
- (and 4 more...)
|
Interventional |
Phase 2 |
- University Hospital, Ghent
- Kom Op Tegen Kanker
- Anticancer Fund, Belgium
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate at week 26
- Incidence of treatment-emergent adverse events (Safety according to CTCAE4.0).
- Objective response rate
- (and 6 more...)
|
43 |
Female |
18 Years and older (Adult, Senior) |
NCT03192059 |
2016-001569-97 |
PRIMMO |
July 1, 2017 |
June 2021 |
June 2022 |
June 19, 2017 |
July 13, 2017 |
|
- University Hospital Antwerp
Antwerp, Belgium - University Hospital Gent
Gent, Belgium - CMSE Namur
Namur, Belgium
|
5 |
NCT02820506 |
Recruiting |
Sentinel Node Mapping in Women With Endometrial and Cervical Cancer |
- Uterine Cervical Neoplasms
- Uterine Neoplasms
|
- Procedure: SLN mapping and removal of PET-positive lymph nodes
|
Interventional |
Not Applicable |
- University of Southern Denmark
- Odense University Hospital
- Danish Cancer Society
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Sensitivity
- Negative predictive value
- Specificity
- (and 5 more...)
|
400 |
Female |
18 Years and older (Adult, Senior) |
NCT02820506 |
SDUSF12015163 1 (198)1 |
SENTIREC II |
February 27, 2017 |
October 2019 |
October 2019 |
July 1, 2016 |
March 22, 2017 |
|
- Rigshospitalet
Copenhagen, Denmark - Herlev Hospital
Herlev, Denmark - Odense University Hospital
Odense, Denmark
|
6 |
NCT02825355 |
Recruiting |
Sentinel Node Mapping in Women With Cervical and Endometrial Cancer |
- Uterine Cervical Neoplasms
- Uterine Neoplasms
|
- Procedure: Sentinel lymph node mapping
|
Interventional |
Not Applicable |
- University of Southern Denmark
- Odense University Hospital
- Danish Cancer Society
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Incidence of lymphedema
- Severity of lymphedema
- Detection rate of sentinel lymph node
- Mapping of SLN in different types of lymph node stations
|
380 |
Female |
18 Years and older (Adult, Senior) |
NCT02825355 |
SDUSF12015163 1 (198) |
SENTIREC I |
February 27, 2017 |
October 2019 |
October 2019 |
July 7, 2016 |
March 22, 2017 |
|
- Rigshospitalet
Copenhagen, Denmark - Herlev Hospital
Herlev, Denmark - Odense University Hospital
Odense, Denmark
|
7 |
NCT00250770 |
Recruiting |
Colony-Stimulating Factor-1 (CSF-1) and Other Cytokines in Human Endometrial Carcinogenesis |
- Uterine Neoplasms
- Endometrial Neoplasms
|
|
Observational |
|
|
Other |
- Observational Model: Case Control
- Time Perspective: Prospective
|
|
750 |
Female |
Child, Adult, Senior |
NCT00250770 |
CSF-1 |
|
January 1998 |
January 2022 |
January 2022 |
November 8, 2005 |
May 12, 2016 |
|
- University of New Mexico
Albuquerque, New Mexico, United States
|
8 |
NCT02986568 |
Recruiting |
Efficacy of the Standard Treatment and Fusion Ontogenetic Surgery for Gynecologic Cancers |
- Cervical Cancer
- Uterine Cancer
|
- Drug: Cisplatin
- Procedure: Peritoneal mesometrial resection
- Procedure: Radical hysterectomy
- (and 7 more...)
|
Interventional |
Not Applicable |
- Seoul National University Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Intraoperative complications
- Acute complications related with surgery
- Chronic complications related with surgery
- (and 3 more...)
|
300 |
Female |
20 Years and older (Adult, Senior) |
NCT02986568 |
2015-1616 |
FUSION IV |
May 2016 |
December 2023 |
|
December 8, 2016 |
December 8, 2016 |
|
- Seoul National University Hospital
Seoul, Korea, Republic of
|
9 |
NCT03241745 |
Recruiting |
A Study of Nivolumab in Selected Uterine Cancer Patients |
- Uterine Cancer
- Endometrial Carcinoma
- Carcinosarcoma
- (and 3 more...)
|
|
Interventional |
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Bristol-Myers Squibb
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-Free Survival
|
40 |
Female |
18 Years and older (Adult, Senior) |
NCT03241745 |
17-180 |
|
August 3, 2017 |
August 2020 |
August 2020 |
August 7, 2017 |
August 7, 2017 |
|
- Memoral Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States - Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States - Memorial Sloan Kettering Commack
Commack, New York, United States - (and 3 more...)
|
10 |
NCT03423082 |
Not yet recruiting |
Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer. |
- Cervical Cancer
- Uterine Cancer
|
- Drug: 18F fluciclovine
- Device: 18F fluciclovine PET
|
Interventional |
Phase 4 |
- Nghi Nguyen
- Blue Earth Diagnostics
- University of Pittsburgh
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Lesion metabolic avidity
- Optimal imaging window
- Fluciclovine PET time-activity curve correlation with histopathologic tumor grading
- Textural tumor heterogeneity
|
10 |
Female |
18 Years and older (Adult, Senior) |
NCT03423082 |
PRO17120310 |
|
April 2018 |
December 31, 2018 |
June 30, 2019 |
February 6, 2018 |
April 5, 2018 |
|
- UPMC Presbyterian - MR Research Center
Pittsburgh, Pennsylvania, United States
|
11 |
NCT03345784 |
Recruiting |
WEE1 Inhibitor AZD1775, External Beam Radiation Therapy, and Cisplatin in Treating Patients With Cervical, Vaginal, or Uterine Cancer |
- Endometrioid Adenocarcinoma
- Recurrent Cervical Carcinoma
- Stage I Uterine Corpus Cancer AJCC v7
- (and 17 more...)
|
- Drug: Adavosertib
- Drug: Cisplatin
- Radiation: External Beam Radiation Therapy
- (and 2 more...)
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- RP2D defined as the dose level with < 1/6 patients with dose limiting toxicities
- Objective response assessed by Response Evaluation Criteria in Solid Tumors 1.1 criteria
- Pharmacodynamic effects of WEE1 inhibitor AZD1775 when given in combination with radiation therapy and cisplatin
- (and 3 more...)
|
24 |
Female |
18 Years and older (Adult, Senior) |
NCT03345784 |
NCI-2017-00038 2013-01765 PHL-087 10132 UM1CA186644 |
|
October 23, 2017 |
October 18, 2020 |
October 18, 2020 |
November 17, 2017 |
March 20, 2018 |
|
- University of California Davis Comprehensive Cancer Center
Sacramento, California, United States - University of Colorado Hospital
Aurora, Colorado, United States - Duke University Medical Center
Durham, North Carolina, United States - University Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
|
12 |
NCT02952183 |
Recruiting |
Efficacy of Pelvic Autonomic Nerve Monitoring System (PAMS I) in Female Patients With Pelvic Tumors |
- Cervical Cancer
- Uterine Cancer
- Ovarian Cancer
|
|
Interventional |
Not Applicable |
- Seoul National University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- Evaluating efficacy of PAMS I by comparison with IOM
- Evaluation of Quality of life.
- Time period for recovering normal voiding function
- (and 2 more...)
|
30 |
Female |
18 Years and older (Adult, Senior) |
NCT02952183 |
2015-2092 |
FUSION V |
July 2015 |
August 2018 |
|
November 2, 2016 |
November 2, 2016 |
|
- Seoul National University Hospital
Seoul, Korea, Republic of
|
13 |
NCT03395080 |
Recruiting |
A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Relapsed/ Refractory Endometrioid Endometrial or Endometrioid Ovarian Cancer (P204) |
- Endometrial Cancer
- Uterine Cancer
- Ovarian Cancer
|
- Drug: Paclitaxel
- Drug: DKN-01
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the objective response rate (ORR).
- To determine the objective disease control rate (ODCR).
- To determine overall survival (OS).
- (and 6 more...)
|
94 |
Female |
18 Years and older (Adult, Senior) |
NCT03395080 |
DEK-DKK1-P204 |
P204 |
February 5, 2018 |
June 2020 |
July 2020 |
January 10, 2018 |
April 18, 2018 |
|
- University of Alabama
Birmingham, Alabama, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - Dana Farber Cancer Institute
Boston, Massachusetts, United States - (and 2 more...)
|
14 |
NCT01870947 |
Recruiting |
Assisted Exercise in Obese Endometrial Cancer Patients |
- Stage I Endometrial Adenocarcinoma
- Uterine Cancer
- Obesity
|
- Behavioral: Exercise on stationary recumbent exercise cycle
- Behavioral: Health Education
- Behavioral: Questionnaires
- (and 2 more...)
|
Interventional |
Not Applicable |
- Case Comprehensive Cancer Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Weight change from pre- to post-intervention
- Change in Body Composition from baseline
- Change in Motivation to Exercise from baseline
- (and 4 more...)
|
120 |
Female |
18 Years and older (Adult, Senior) |
NCT01870947 |
CASE5811 |
|
September 7, 2011 |
March 2018 |
March 2018 |
June 6, 2013 |
April 25, 2017 |
|
- Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States - The Cleveland Clinic Foundation
Cleveland, Ohio, United States
|
15 |
NCT01344837 |
Not yet recruiting |
Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer |
- Endometrial Serous Adenocarcinoma
- Stage I Uterine Corpus Cancer
- Stage II Uterine Corpus Cancer
- (and 2 more...)
|
- Other: Diagnostic Laboratory Biomarker Analysis
- Other: Immunohistochemistry Staining Method
- Other: Medical Chart Review
- (and 3 more...)
|
Observational |
|
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Overall survival
- Presence of synchronous or metachronous breast cancer
- Progression-free survival
|
360 |
Female |
Child, Adult, Senior |
NCT01344837 |
GOG-8023 NCI-2011-02872 CDR0000698458 R21CA135467 U10CA027469 U10CA037517 |
|
January 2100 |
January 2100 |
|
April 29, 2011 |
May 29, 2015 |
|
- Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States
|
16 |
NCT01953107 |
Recruiting |
Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. |
- Ovarian Cancer
- Cervical Cancer
- Uterine Cancer
- Anemia
|
- Other: Oral Ferrous Fumarate
- Other: Placebo
|
Interventional |
Phase 4 |
- Sunnybrook Health Sciences Centre
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Supportive Care
|
- Mean Difference in Hemoglobin
- Quality of life
|
200 |
Male |
18 Years and older (Adult, Senior) |
NCT01953107 |
GYNEOCC2 |
|
November 2013 |
January 2017 |
November 2017 |
September 30, 2013 |
April 25, 2017 |
|
- Odette Cancer Centre
Toronto, Ontario, Canada
|
17 |
NCT03073525 |
Recruiting |
Trial of Atezolizumab and Vigil for Advanced Gynecological Cancers (A Companion Study to CL-PTL-119) |
- Advanced Gynecological Cancers
- Ovarian Cancer
- Cervical Cancer
- Uterine Cancer
|
- Biological: Vigil
- Drug: Atezolizumab
|
Interventional |
Phase 2 |
- Gradalis, Inc.
- Roche-Genentech
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of treatment-emergent AEs of Vigil + Atezolizumab
- ELISPOT conversion rate to Vigil alone, Atezolizumab alone and Vigil + Atezolizumab
- Radiological Tumor Assessment
- Time to Progression
|
25 |
Female |
18 Years and older (Adult, Senior) |
NCT03073525 |
CL-PTL-126 |
|
May 25, 2017 |
October 1, 2018 |
April 1, 2019 |
March 8, 2017 |
February 21, 2018 |
|
- University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Augusta University
Augusta, Georgia, United States - Henry Ford Health System
Detroit, Michigan, United States - (and 3 more...)
|
18 |
NCT02822833 |
Recruiting |
The Role of Indocyanine Green to Identify Sentinel Lymph Node in Uterine Cancer |
|
- Procedure: Sentinel lymph node mapping
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Sensitivity and specificity of sentinel lymph node frozen section
- Unilateral or bilateral sentinel lymph node detection rate by indocyanine green
- Negative and positive predictive values for sentinel lymph node frozen section
|
100 |
Female |
18 Years and older (Adult, Senior) |
NCT02822833 |
04 |
|
July 2016 |
June 2017 |
June 2017 |
July 4, 2016 |
September 13, 2016 |
|
- Ankara University School of Medicine Department of Ob&Gyn
Ankara, Turkey
|
19 |
NCT01686126 |
Recruiting |
Improving the Treatment for Women With Early Stage Cancer of the Uterus |
- Complex Endometrial Hyperplasia With Atypia
- Grade 1 Endometrial Endometrioid Adenocarcinoma
|
- Drug: Levonorgestrel
- Drug: Metformin
|
Interventional |
Phase 2 |
- Queensland Centre for Gynaecological Cancer
- The University of Queensland
- Queensland University of Technology
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pathological complete response
- Predict the response to treatment
|
165 |
Female |
18 Years and older (Adult, Senior) |
NCT01686126 |
feMMe |
feMMe |
December 2012 |
December 2019 |
December 2020 |
September 17, 2012 |
April 5, 2018 |
|
- Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia - John Hunter Hospital
New Lambton, New South Wales, Australia - The Wesley Hospital
Auchenflower, Queensland, Australia - (and 16 more...)
|
20 |
NCT03379376 |
Not yet recruiting |
EHealth Mindful Movement and Breathing in Improving Outcomes in Participants Undergoing Gynecologic Surgery |
- Female Reproductive System Neoplasm
- Malignant Female Reproductive System Neoplasm
- Malignant Uterine Neoplasm
- (and 4 more...)
|
- Other: Questionnaire Administration
- Procedure: Supportive Care
|
Interventional |
Not Applicable |
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- A refined manual for intervention implementation for the next phase of the study
- Recruitment
- Adherence
- (and 3 more...)
|
15 |
Female |
18 Years and older (Adult, Senior) |
NCT03379376 |
CCCWFU 04517 NCI-2018-00584 P30CA012197 |
|
May 1, 2018 |
May 1, 2019 |
May 2020 |
December 20, 2017 |
April 17, 2018 |
|
- Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
|
21 |
NCT03367923 |
Recruiting |
Health and Recovery Program in Increasing Physical Activity Level in Stage IA-IIIA Endometrial Cancer Survivors |
- Cancer Survivor
- Endometrial Carcinoma
- Stage I Uterine Corpus Cancer AJCC v7
- (and 4 more...)
|
- Other: Communication Intervention
- Other: Counseling
- Other: Fitbit tracker
- (and 3 more...)
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Increase in activity level measured using Fitbit tracker
- Body mass index (BMI)
- Pulse
- (and 4 more...)
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT03367923 |
GYNEND0002 NCI-2017-02149 43094 |
|
December 1, 2017 |
April 1, 2020 |
April 1, 2021 |
December 11, 2017 |
March 7, 2018 |
|
- Stanford University, School of Medicine
Palo Alto, California, United States - Stanford Cancer Center South Bay
San Jose, California, United States
|
22 |
NCT03367741 |
Recruiting |
Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer |
- Recurrent Uterine Corpus Carcinoma
- Stage III Uterine Corpus Cancer AJCC v7
- Stage IIIA Uterine Corpus Cancer AJCC v7
- (and 7 more...)
|
- Drug: Cabozantinib
- Other: Laboratory Biomarker Analysis
- Biological: Nivolumab
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression free survival (PFS)
- Overall response rate (ORR)
- Overall survival (OS)
- (and 2 more...)
|
54 |
All |
18 Years and older (Adult, Senior) |
NCT03367741 |
NCI-2017-02211 PHL-099 10104 UM1CA186644 |
|
January 26, 2018 |
January 23, 2021 |
January 23, 2021 |
December 11, 2017 |
April 10, 2018 |
|
- University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States - UC Comprehensive Cancer Center at Silver Cross
New Lenox, Illinois, United States - University of Chicago Medicine-Orland Park
Orland Park, Illinois, United States - (and 2 more...)
|
23 |
NCT03309709 |
Recruiting |
Endometrial Polyps Regression With Progesterone Therapy |
|
- Drug: subcutaneous progesterone
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Polyps regression rate
- Polyps dimensions
- Correlation between polyps dimension and regression
- (and 2 more...)
|
66 |
Female |
18 Years to 50 Years (Adult) |
NCT03309709 |
Progesterone Polyps |
|
October 8, 2017 |
October 30, 2018 |
December 30, 2018 |
October 13, 2017 |
March 13, 2018 |
|
- Ospedale Pugliese Ciaccio
Catanzaro, Calabria, Italy
|
24 |
NCT03164590 |
Recruiting |
Effects of Wound Infiltration With Ketamine Versus Dexmedetomidine Added to Bupivacaine on Cytokines |
- Endometrial Adenocarcinoma
|
- Drug: Ketamine
- Drug: dexmedetomidine
- Drug: bupivacaine
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- severity of pain at rest and on coughing
- sedation
|
90 |
Female |
18 Years to 60 Years (Adult) |
NCT03164590 |
388 |
|
June 1, 2017 |
April 2018 |
April 2018 |
May 23, 2017 |
April 3, 2018 |
|
- South Egypt Cancer instIitute
Assuit, Egypt
|
25 |
NCT02472197 |
Recruiting |
Morcellator Versus Resectoscope in the Treatment of Uterine Polyps by Hysteroscopy |
|
- Procedure: Hysteroscopic morcellation
- Procedure: Standard hysteroscopic resection
|
Interventional |
Not Applicable |
- University Hospital, Strasbourg, France
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Morcellation or resection time (minutes)
- The completeness of resection or not,
- The total operating time (in minutes):
- (and 5 more...)
|
90 |
Female |
18 Years and older (Adult, Senior) |
NCT02472197 |
6043 |
RESMO |
September 2015 |
January 2019 |
January 2019 |
June 15, 2015 |
September 8, 2017 |
|
- University Hospital, Strasbourg, france
Strasbourg, France
|
26 |
NCT01198171 |
Not yet recruiting |
Racial and Genetic Biomarkers of Response in Tissue Samples From Patients With Endometrial Cancer |
- Stage I Uterine Corpus Cancer
- Stage II Uterine Corpus Cancer
- Stage III Uterine Corpus Cancer
- Stage IV Uterine Corpus Cancer
|
- Other: Laboratory Biomarker Analysis
- Other: Study of Socioeconomic and Demographic Variables
|
Observational |
|
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Time Perspective: Retrospective
|
- Clinicopathologic and demographic characteristics: characteristics: self-reported race, stage, age, race, parity, body-mass index, stage, grade, depth of invasion, lymph-vascular space invasion, and metastasis
- Overall survival
- Progression-free survival
- (and 2 more...)
|
243 |
Female |
Child, Adult, Senior |
NCT01198171 |
GOG-8022 NCI-2011-02867 CDR0000684547 P50CA134254 R01CA071754 R21CA133295 U10CA027469 U10CA037517 |
|
January 2100 |
January 2100 |
|
September 9, 2010 |
May 29, 2015 |
|
- Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States
|
27 |
NCT01164735 |
Not yet recruiting |
Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer |
- Recurrent Uterine Corpus Carcinoma
- Stage III Uterine Corpus Cancer
- Stage IV Uterine Corpus Cancer
|
- Other: Laboratory Biomarker Analysis
|
Observational |
|
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Overall survival
- Clinical response (complete or partial response)
- Progression-free survival
|
169 |
Female |
18 Years and older (Adult, Senior) |
NCT01164735 |
GOG-8013 NCI-2011-02245 CDR0000681556 U10CA027469 |
|
January 2100 |
January 2100 |
|
July 19, 2010 |
June 8, 2015 |
|
- Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States
|
28 |
NCT03325634 |
Recruiting |
Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Primary Ovarian or Uterine Cancer |
- Recurrent Endometrial Serous Adenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
|
- Other: Laboratory Biomarker Analysis
- Other: Quality-of-Life Assessment
- Other: Questionnaire Administration
- Radiation: Stereotactic Body Radiation Therapy
|
Interventional |
Phase 1 |
- University of Colorado, Denver
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose
- Chemotherapy-free interval
- incidence of late toxicity
- (and 3 more...)
|
30 |
Female |
18 Years and older (Adult, Senior) |
NCT03325634 |
17-1333.cc NCI-2017-01888 17-1333 P30CA046934 |
|
December 5, 2017 |
October 9, 2019 |
October 9, 2019 |
October 30, 2017 |
December 12, 2017 |
|
- University of Colorado Hospital
Aurora, Colorado, United States
|
29 |
NCT02874430 |
Recruiting |
Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer |
- Breast Carcinoma
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- (and 2 more...)
|
- Drug: Metformin Hydrochloride
- Drug: Doxycycline
|
Interventional |
Phase 2 |
- Sidney Kimmel Cancer Center at Thomas Jefferson University
- Thomas Jefferson University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in the percent of stromal cells expressing Caveolin-1 (CAV1) at an intensity of 1+ or greater assessed by immunohistochemistry
- Incidence of adverse events evaluated using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Change in the percent of stromal cells expressing express Monocarboxylate Transporter 4 (MCT4) in the cancer cells
- (and 6 more...)
|
46 |
Female |
18 Years and older (Adult, Senior) |
NCT02874430 |
16D.317 |
|
June 8, 2016 |
February 2021 |
January 2022 |
August 22, 2016 |
March 16, 2018 |
|
- Thomas Jefferson University
Philadelphia, Pennsylvania, United States
|
30 |
NCT02993900 |
Recruiting |
Image-Guided Gynecologic Brachytherapy |
- Cervical Cancer
- Uterine Cancer
- Vaginal Cancer
- (and 2 more...)
|
- Device: Image-Guided Brachytherapy
|
Interventional |
Phase 2 |
- Sidney Kimmel Comprehensive Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dosing changes
- The rate of treatment-related toxicity
- Time to local failure
- Rate of survival
|
54 |
Female |
18 Years to 100 Years (Adult, Senior) |
NCT02993900 |
J1660 IRB00098525 |
|
September 2016 |
September 2021 |
|
December 15, 2016 |
December 12, 2017 |
|
- The SKCCC at Johns Hopkins
Baltimore, Maryland, United States
|
31 |
NCT02714621 |
Recruiting |
MR-HIFU for Recurrent Gynaecological Cancer |
- Cervical Cancer
- Endometrial Cancer
- Uterine Cancer
- (and 3 more...)
|
- Device: Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)
|
Interventional |
Not Applicable |
- Institute of Cancer Research, United Kingdom
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Changes in pain, measured using a patient diary
- Changes in bleeding, measured using a questionnaire
|
35 |
Female |
18 Years and older (Adult, Senior) |
NCT02714621 |
15/WM/0470 CCR4360 |
HIFU-Gynae |
May 2016 |
May 2019 |
May 2019 |
March 21, 2016 |
January 12, 2017 |
|
- The Royal Marsden NHS Foundation Trust
Surrey, United Kingdom
|
32 |
NCT02549209 |
Recruiting |
Pembro/Carbo/Taxol in Endometrial Cancer |
- Endometrial Cancer
- Endometrial Adenocarcinoma
|
- Drug: Pembrolizumab
- Drug: Paclitaxel
- Drug: Carboplatin
|
Interventional |
Phase 2 |
- Daniela Matei, MD
- Merck Sharp & Dohme Corp.
- Hoosier Cancer Research Network
- Big Ten Cancer Research Consortium
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rates (ORR)
- Incidence of Adverse Events as a Measure of Safety and Tolerability
|
46 |
Female |
18 Years and older (Adult, Senior) |
NCT02549209 |
BTCRC GYN15-013 |
|
August 22, 2017 |
May 2018 |
November 2019 |
September 15, 2015 |
February 8, 2018 |
|
- Northwestern University, Robert H. Lurie Cancer Center
Chicago, Illinois, United States - Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
|
33 |
NCT01199250 |
Not yet recruiting |
Biomarkers in Samples From Patients With Endometrial Cancer |
- Lynch Syndrome
- Recurrent Uterine Corpus Carcinoma
- Stage I Uterine Corpus Cancer
- (and 3 more...)
|
- Other: Laboratory Biomarker Analysis
|
Observational |
|
- Gynecologic Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Time Perspective: Retrospective
|
- Clinical sensitivity and specificity of epigenetic biomarkers in a cohort of blind samples (Project 2)
- Confirmation of CpG island loci frequently hypermethylated in EECs exhibiting recurrence (Project 2)
- Development of a molecular screening regimen to compliment family history risk assessment for the detection of Lynch syndrome (Project 3)
- (and 9 more...)
|
3600 |
Female |
Child, Adult, Senior |
NCT01199250 |
GOG-8020 NCI-2011-02868 CDR0000684553 P50CA134254 R01CA071754 R21CA133295 U10CA027469 U10CA037517 |
|
January 2100 |
January 2100 |
|
September 10, 2010 |
May 29, 2015 |
|
- Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States
|
34 |
NCT01537822 |
Recruiting |
The Hysteroscopic Morcellator (HM). |
- Large Intrauterine Polyps
- Smaller Type 0 and 1 Myomas
- Residual Placental Tissue
|
- Procedure: Hysteroscopic morcellator
- Procedure: Resectoscope
|
Interventional |
Not Applicable |
- University Hospital, Ghent
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Installation time and operating time.
- Check for adhesions during follow-up.
- Fluid deficit
- complications and complaints
|
222 |
Female |
18 Years and older (Adult, Senior) |
NCT01537822 |
2011/679 |
HM |
May 2011 |
July 2018 |
December 2018 |
February 23, 2012 |
February 13, 2018 |
|
- Ghent University Hospital
Ghent, Belgium - Catharina Hospital Eindhoven
Eindhoven, Netherlands
|
35 |
NCT01447199 |
Recruiting |
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC) |
- Bladder Cancer
- Colorectal Cancer
- Endometrial Cancer
- (and 3 more...)
|
- Behavioral: Health and Diet Questionnaire
|
Observational |
|
- M.D. Anderson Cancer Center
|
Other |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Time to Onset for Colorectal Cancer
|
2000 |
All |
18 Years and older (Adult, Senior) |
NCT01447199 |
DM94-060 |
|
September 1994 |
September 2019 |
September 2019 |
October 6, 2011 |
January 17, 2018 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
36 |
NCT03133286 |
Recruiting |
Radiotherapy Assessments During Intervention ANd Treatment (RADIANT) |
- Radiation Therapy
- Cancer
- Cancer of Anus
- (and 16 more...)
|
|
Observational |
|
- DxTerity Diagnostics
- National Cancer Institute (NCI)
|
Industry / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Obtain pre- and post-irradiation participant-collect blood samples
|
500 |
All |
18 Years and older (Adult, Senior) |
NCT03133286 |
DXT-RADTOX-AC03 HHSN261201600051C |
RADIANT |
April 6, 2017 |
September 6, 2018 |
September 6, 2018 |
April 28, 2017 |
May 4, 2017 |
|
- DxTerity Diagnostics
Compton, California, United States
|
37 |
NCT03215511 |
Recruiting |
Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers |
- Carcinoma, Non-Small-Cell Lung
- Thyroid Neoplasms
- Sarcoma
- (and 32 more...)
|
|
Interventional |
Phase 1 Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose (MTD)
- Recommended dose for further study in patients age 12 and older and age <12
- Best overall response of confirmed PR or CR by independent radiology review in patients age 12 and older and age <12 in NTRK fusion cancer patients previously treated with TRK inhibitor who have progressed
- (and 14 more...)
|
93 |
All |
1 Month and older (Child, Adult, Senior) |
NCT03215511 |
LOXO-EXT-17005 |
|
July 10, 2017 |
August 2019 |
December 2019 |
July 12, 2017 |
March 1, 2018 |
|
- Stanford Cancer Center
Stanford, California, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - Memorial Sloan Kettering Cancer Center
New York, New York, United States - MD Anderson Cancer Center
Houston, Texas, United States
|
38 |
NCT02465060 |
Recruiting |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) |
- Advanced Malignant Solid Neoplasm
- Bladder Carcinoma
- Breast Carcinoma
- (and 47 more...)
|
- Drug: Adavosertib
- Drug: Afatinib
- Drug: Binimetinib
- (and 21 more...)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate, defined as the percentage of patients whose tumors have a complete or partial response to treatment
- Overall survival, evaluated specifically for each drug (or step)
- Progression free survival
- Time to progression
|
6452 |
All |
18 Years and older (Adult, Senior) |
NCT02465060 |
NCI-2015-00054 EAY131 U10CA180820 U24CA196172 |
|
August 12, 2015 |
June 30, 2022 |
|
June 8, 2015 |
April 17, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 1211 more...)
|
39 |
NCT02349958 |
Recruiting |
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy |
- Ovarian Cancer
- Peritoneal Cancer
- Fallopian Tube Cancer
- (and 4 more...)
|
- Device: HIPEC: MMC 30mg @ T0, 10mg @ T45min
- Device: HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0
- Device: HIPEC: CDDP 75 mg/m2 @T0
- Device: HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0
|
Interventional |
Phase 2 |
- Bay Area Gynecology Oncology
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- measure treatment response to HIPEC and tumor debulking
- Toxicity Monitoring
|
200 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02349958 |
HIPEC |
HIPEC/IPHC |
September 2006 |
January 2018 |
January 2018 |
January 29, 2015 |
February 1, 2017 |
|
- James Lilja
Los Gatos, California, United States
|
40 |
NCT03021200 |
Recruiting |
Laser Fluorescence in Cancer Surgical Treatment |
- Esophageal Cancer
- Gastric Cancer
- ColoRectal Cancer
- (and 4 more...)
|
- Device: Green indocianine
|
Interventional |
Not Applicable |
- Instituto do Cancer do Estado de São Paulo
- Ministério da Saúde
- Fundação Faculdade de Medicina
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Intestinal Anastomosis Fistula
- Esophageal fistula
- positive lymph nodes
- (and 5 more...)
|
270 |
All |
18 Years and older (Adult, Senior) |
NCT03021200 |
NP953/16 |
|
July 12, 2016 |
June 30, 2017 |
June 2020 |
January 13, 2017 |
June 29, 2017 |
|
- Ulysses Ribeiro Junior
Sao Paulo, São Paulo, Brazil
|
41 |
NCT02501954 |
Recruiting |
Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol |
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- Stage IIIA Uterine Corpus Cancer
- (and 3 more...)
|
- Drug: Cisplatin
- Drug: Carboplatin
- Drug: Paclitaxel
- Radiation: Radiation Therapy
|
Interventional |
Phase 3 |
- Women's Cancer Care Associates, LLC
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recurrence-free survival (RFS)
- Overall survival (OS)
|
450 |
Female |
18 Years and older (Adult, Senior) |
NCT02501954 |
15-07 |
|
March 2015 |
March 2020 |
March 2023 |
July 17, 2015 |
November 1, 2017 |
|
- Women's Cancer Care Associates, LLC
Albany, New York, United States - The Ohio State University
Columbus, Ohio, United States - CHUM Hopital Notre-Dame
Montréal, Quebec, Canada
|
42 |
NCT03206177 |
Recruiting |
Paclitaxel/Carboplatin + Galunisertib for Patients With Carcinosarcoma of the Uterus or Ovary |
|
- Drug: Galunisertib
- Drug: Paclitaxel
- Drug: Carboplatin
|
Interventional |
Phase 1 |
- University of Oklahoma
- Eli Lilly and Company
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients who completed 4 cycles of treatment
- Adverse Events
- Progression Free Survival
- (and 2 more...)
|
20 |
Female |
18 Years to 99 Years (Adult, Senior) |
NCT03206177 |
7934 |
|
August 20, 2017 |
June 1, 2019 |
June 1, 2022 |
July 2, 2017 |
September 26, 2017 |
|
- University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
|
43 |
NCT03042897 |
Recruiting |
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer |
- Estrogen Receptor Positive
- Obesity
- Progesterone Receptor Positive
- (and 3 more...)
|
- Dietary Supplement: Dietary Intervention
- Behavioral: Exercise Intervention
- Other: Laboratory Biomarker Analysis
- Other: Quality-of-Life Assessment
|
Interventional |
Not Applicable |
- University of Southern California
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Cardiorespiratory Fitness (CRF)
- Cardiovascular (CV) health outcomes
- Depression measured by Center for Epidemiologic Studies Depression scale
- (and 4 more...)
|
25 |
Female |
19 Years and older (Adult, Senior) |
NCT03042897 |
5U-16-1 NCI-2016-01684 P30CA014089 |
|
September 8, 2017 |
September 8, 2018 |
September 8, 2019 |
February 3, 2017 |
December 20, 2017 |
|
- USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
|
44 |
NCT01970722 |
Recruiting |
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer |
- Recurrent Uterine Corpus Cancer
- Recurrent Fallopian Tube Cancer
- Recurrent Ovarian Cancer
- (and 18 more...)
|
- Procedure: therapeutic conventional surgery
- Drug: cisplatin
- Drug: carboplatin
- (and 5 more...)
|
Interventional |
Phase 1 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Treatment-related toxicities according to NCI CTCAE guidelines
- QoL assessed by the Functional Assessment of Cancer Therapy-Ovarian (FACT-O) QoL questionnaire
- PFS
|
50 |
Female |
18 Years and older (Adult, Senior) |
NCT01970722 |
12316 NCI-2013-01948 |
|
May 2014 |
May 2020 |
May 2020 |
October 28, 2013 |
February 15, 2018 |
|
- City of Hope Corona
Corona, California, United States - City of Hope Medical Center
Duarte, California, United States - City of Hope Rancho Cucamonga
Rancho Cucamonga, California, United States
|
45 |
NCT01130519 |
Recruiting |
A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer |
- HLRCC
- Metastatic Papillary RCC
|
- Drug: Bevacizumab
- Drug: Erlotinib
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate
- Progression-free survival, duration of response, and overall survival.
- Effect on potential biomarkers of angiogenesis in plasma such as VEGF and soluble VEGFR2.
- (and 5 more...)
|
85 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT01130519 |
100114 10-C-0114 |
|
May 4, 2010 |
January 1, 2019 |
June 30, 2019 |
May 26, 2010 |
March 2, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
46 |
NCT02115477 |
Recruiting |
Lymphedema After Primary Surgery for Endometrial Cancer |
- Carcinoma of the Endometrium
- Hysterectomy
- Lymphadenectomy
|
- Procedure: Lymphadenectomy
|
Observational |
|
- Preben Kjolhede, MD, professor
- Swedish Cancer Society
- Medical Research Council of Southeast Sweden
- (and 3 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change in leg volume from baseline (preoperatively) to 4-6 weeks postoperatively
- Change in leg volume from baseline (preoperatively) to 6 months postoperatively
- Change in leg volume from baseline (preoperatively) to 12 months postoperatively
- (and 5 more...)
|
260 |
Female |
18 Years and older (Adult, Senior) |
NCT02115477 |
Version 2013-09-22/2014-03-21 The Swedish Cancer Society |
LASEC |
April 2014 |
June 2017 |
June 2018 |
April 16, 2014 |
February 23, 2016 |
|
- Highland hospital
Eksjo, Jonkopings län, Sweden - Falu Central Hospital
Falun, Sweden - Gävle County Hospital
Gävle, Sweden - (and 13 more...)
|
47 |
NCT02495103 |
Recruiting |
Vandetanib in Combination With Metformin in People With HLRCC or SDH-Associated Kidney Cancer or Sporadic Papillary Renal Cell Carcinoma |
- Renal Cell Carcinoma
- Hereditary Leiomyomatosis and Renal Cell Cancer
- Papillary Renal Cell Carcinoma, Sporadic
|
- Drug: Vandetanib
- Drug: Metformin
- Drug: Vandetanib/Metformin
|
Interventional |
Phase 1 Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase 1 Component: To establish the safety and maximum tolerated dose (MTD) of vandetanib and metformin when used in combination in patients with metastatic RCC.
- Phase 2 Component: To determine the overall response rate (RECIST 1.1) following treatment with the combination of vandetanib and metformin in patients with 1) advanced RCC associated with HLRCC or SDH, and 2) advanced sporadic/non-HLRCC papilla...
- Phase 1 Component: Evaluate the clinical activity of the combination of vandetanib and metformin
- (and 6 more...)
|
73 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT02495103 |
150157 15-C-0157 |
|
July 8, 2015 |
May 1, 2021 |
May 1, 2022 |
July 13, 2015 |
April 4, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
48 |
NCT03302156 |
Recruiting |
PSMA PET and MRI in Gynecological Cancers |
|
- Drug: PSMA-based 18F-DCFPyL PET tracer
|
Interventional |
Phase 2 |
- University of Wisconsin, Madison
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Diagnostic accuracy
- Biodistribution of PSMA
- Radiodosimetry of PSMA
- Sensitivity and specificity of PSMA-based PET/MR
|
52 |
Female |
18 Years to 99 Years (Adult, Senior) |
NCT03302156 |
2017-0456 UW17017 |
|
August 10, 2017 |
August 1, 2019 |
August 1, 2020 |
October 4, 2017 |
March 13, 2018 |
|
- University of Wisconsin, Madison
Madison, Wisconsin, United States
|
49 |
NCT03422198 |
Recruiting |
Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer |
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Endometrioid Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- (and 6 more...)
|
- Radiation: Vaginal Cuff Brachytherapy
- Radiation: Short course vaginal cuff brachytherapy
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Health related quality of life (HRQOL) using the Global Health Score from the Quality of Life Questionnaire Core 30 (QLQ-C30)
- Treatment-related symptoms on HRQOL using European Organization for Research and Treatment of Cancer Endometrial Cancer Module (EORTC EN24), question 48
- Cost effectiveness (CE)
|
108 |
All |
Child, Adult, Senior |
NCT03422198 |
HCI103841 NCI-2018-00011 |
SAVE |
January 17, 2018 |
January 8, 2022 |
January 8, 2022 |
February 5, 2018 |
April 19, 2018 |
|
- Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, United States
|
50 |
NCT03120624 |
Recruiting |
VSV-hIFNbeta-NIS in Treating Patients With Stage IV or Recurrent Endometrial Cancer |
- Endometrial Clear Cell Adenocarcinoma
- Endometrial Mixed Adenocarcinoma
- Endometrial Serous Adenocarcinoma
- (and 8 more...)
|
- Procedure: Biopsy
- Procedure: Computed Tomography
- Other: Laboratory Biomarker Analysis
- (and 5 more...)
|
Interventional |
Phase 1 |
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of adverse events graded according to the NCI CTCAE version 4
- Maximum tolerated dose of VSV-hIFNbeta-NIS graded according to the National Cancer Institute (NCI) CTCAE version 4
- Biodistribution and kinetics of virus spread and NIS gene expression in vivo assessed via SPECT/CT
- (and 4 more...)
|
33 |
Female |
18 Years and older (Adult, Senior) |
NCT03120624 |
MC1562 NCI-2017-00615 P30CA015083 |
|
September 15, 2017 |
June 2019 |
June 2019 |
April 19, 2017 |
March 15, 2018 |
|
- Mayo Clinic
Rochester, Minnesota, United States
|